BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36651271)

  • 1. The frequency of rs2231142 in
    Alrajeh K; Roman YM
    Pharmacogenomics; 2023 Jan; 24(1):15-26. PubMed ID: 36651271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The frequency of rs2231142 in
    AlAzzeh O; Roman YM
    Pharmacogenomics; 2023 Feb; 24(3):173-182. PubMed ID: 36661065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The frequency of major
    Alrajeh K; AlAzzeh O; Roman Y
    Pharmacogenomics; 2023 May; 24(7):381-398. PubMed ID: 37222158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Wei C; Chen Y; Mosqueda-Garcia R; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):341-55. PubMed ID: 25673568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
    Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
    Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.
    Hu M; To KK; Mak VW; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):49-62. PubMed ID: 21091277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.
    Birmingham BK; Bujac SR; Elsby R; Azumaya CT; Zalikowski J; Chen Y; Kim K; Ambrose HJ
    Eur J Clin Pharmacol; 2015 Mar; 71(3):329-40. PubMed ID: 25630984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of ABCG2 loss of function variant (p. Gln141Lys, c.421 C > A, rs2231142) on lipid levels and statin efficiency: a systematic review and meta-analysis.
    Liu Y; Chen Y; Wei B; Li H; Peng Y; Luo Z
    BMC Cardiovasc Disord; 2024 Apr; 24(1):202. PubMed ID: 38589776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
    Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
    Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
    DeGorter MK; Tirona RG; Schwarz UI; Choi YH; Dresser GK; Suskin N; Myers K; Zou G; Iwuchukwu O; Wei WQ; Wilke RA; Hegele RA; Kim RB
    Circ Cardiovasc Genet; 2013 Aug; 6(4):400-8. PubMed ID: 23876492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions.
    Sakiyama M; Matsuo H; Takada Y; Nakamura T; Nakayama A; Takada T; Kitajiri S; Wakai K; Suzuki H; Shinomiya N
    Drug Metab Pharmacokinet; 2014; 29(6):490-2. PubMed ID: 24869748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin.
    Hu M; Lee HK; To KK; Fok BS; Wo SK; Ho CS; Wong CK; Zuo Z; Chan TY; Chan JC; Tomlinson B
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1471-1478. PubMed ID: 27651239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
    Zhang D; Ding Y; Wang X; Xin W; Du W; Chen W; Zhang X; Li P
    Eur J Clin Pharmacol; 2020 Jul; 76(7):939-946. PubMed ID: 32361904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote.
    Wan Z; Wang G; Li T; Xu B; Pei Q; Peng Y; Sun H; Cheng L; Zeng Y; Yang G; Zhu YS
    J Pharmacol Exp Ther; 2015 Sep; 354(3):310-5. PubMed ID: 26081159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrasting roles of the ABCG2 Q141K variant in prostate cancer.
    Sobek KM; Cummings JL; Bacich DJ; O'Keefe DS
    Exp Cell Res; 2017 May; 354(1):40-47. PubMed ID: 28300564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of ABCG2 Q141K and Q126X genotyping in predicting risk of preeclampsia in Chinese Han women population.
    Hou H; Geng M; Zhang R; Liu W; Wang J; Li J; Lin Y; Liu S; Wang Z; Guo H; Guan H; Tan P
    Pregnancy Hypertens; 2019 Jul; 17():197-202. PubMed ID: 31487640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
    Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.
    Wu HF; Hristeva N; Chang J; Liang X; Li R; Frassetto L; Benet LZ
    J Pharm Sci; 2017 Sep; 106(9):2751-2757. PubMed ID: 28385543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.
    Kim IS; Kim HG; Kim DC; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Lee GW
    Cancer Sci; 2008 Dec; 99(12):2496-501. PubMed ID: 19032367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.